Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jennifer Rumpel

Allergy & Immunology Portage, IN Medical Doctor

NPI 1588827562 CMS profile 207460

6375 US Highway 6 Ste C, Portage, IN 46368

Open in the dashboard

General payments

$14,104

838 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jennifer Rumpel of Portage, IN is reported in the CMS Open Payments database as having received $14,104 across 838 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,875 157
2024 General $2,308 120
2023 General $2,223 127
2022 General $2,581 168
2021 General $2,060 133
2020 General $1,355 80
2019 General $702 53

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jennifer Rumpel
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Jennifer Rumpel were reported at $2,875. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Jennifer Rumpel Allergy & Immunology median Middle half National median
2019 $702 $594 $163–$1,512 $163
2020 $1,355 $426 $106–$1,233 $114
2021 $2,060 $638 $157–$1,708 $132
2022 $2,581 $790 $205–$1,961 $149
2023 $2,223 $852 $220–$2,147 $160
2024 $2,308 $865 $203–$2,267 $164
2025 $2,875 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $2,125 112 payments
  2. OptiNose US, Inc. $1,584 128 payments
  3. GlaxoSmithKline, LLC. $1,571 127 payments
  4. Regeneron Healthcare Solutions, Inc. $1,386 74 payments
  5. Genzyme Corporation $1,292 55 payments
  6. ALK-Abello, Inc $897 53 payments
  7. Novartis Pharmaceuticals Corporation $755 48 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $735 44 payments
  9. CSL Behring $494 29 payments
  10. Grifols USA, LLC $448 25 payments
  11. Other $2,817 143 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $13,890 825 payments
  2. Education $161 9 payments
  3. Consulting Fee $53 4 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Immunology $2,146 93 payments
  2. Xhance $1,584 128 payments
  3. DUPIXENT Inflammation And Immunology $1,067 56 payments
  4. NUCALA $851 66 payments
  5. Odactra $844 50 payments
  6. FASENRA $816 33 payments
  7. Grastek $711 42 payments
  8. Ragwitek $637 38 payments
  9. TEZSPIRE $537 15 payments
  10. AIRSUPRA $458 17 payments
  11. Other $7,322 421 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

1,022

Median for Allergy/ Immunology: 449

Drug cost

$682,088

Median for Allergy/ Immunology: $169,700

Branded share of claims

41.3%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tezspire Tezepelumab-Ekko Brand 42 $177,050
Nucala Mepolizumab Brand 34 $124,411
Xolair Omalizumab Brand 33 $96,918
Hyqvia Igg/Hyaluronidase,recombinant Brand 13 $90,851
Dupixent Syringe Dupilumab Brand 13 $67,323
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 44 $36,937
Advair Hfa Fluticasone Propion/Salmeterol Brand 44 $19,714
Breo Ellipta Fluticasone/Vilanterol Brand 36 $16,636
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 25 $14,685
Xhance Fluticasone Propionate Brand 11 $6,780

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$47,643

Of which drugs: $1,778

Medicare patients

127

Average age 69

Services billed

6,346

100 women, 27 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 53%
Diabetes 25%
COPD 25%
Depression 25%
Ischemic heart disease 17%
Chronic kidney disease 16%
Cancer 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 11 11 $818

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$656 13 —
Xhance
$281 11 —
NUCALA
$182 34 —
AIRSUPRA
$144 — —
TEZSPIRE
$138 42 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

838 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record